Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Complement System

Written/Edited by Julian Pampel, BSc

The complement system is part of the innate immune system and plays an important role in the host defense, inflammation, tissue regeneration and other physiological processes. Complement activation results in opsonization of pathogens and their removal by phagocytes. It also causes chemotactic attraction of phagocytes and macrophages. Furthermore, the complement system forms the terminal attack complex (MAC), a membrane channel causing osmotic lysis of the respective pathogen. While complement is not adaptable it does complement the adaptive immune system and it is also involved in B and T cell response regulation.

Activation of Complement System

Activation of complement unfolds along three different complement activation pathways depending on the nature of the pathogen: The classical pathway, the lectin pathway, and the alternative pathway. All three converge into the common terminal pathway that leads to the formation of the MAC. In addition, anaphylatoxins C3a and C5a elicit a plethora of physiological responses that range from chemoattraction to apoptosis. The complement system consists of more than 30 proteins that are either present as soluble proteins in the blood or as membrane-associated proteins. Most exist as inactive zymogens that are then sequentially cleaved and activated. The central component in all three pathways is component C3, the most abundant complement protein found in the blood. Its activation induces the formation of the activation products C3a, C3b, and C5a and ultimately the MAC. In addition to these three established pathways, it has been shown that factors such as kallikrein, plasmin, thrombin, and factor XIIa activate the complement system independently of the C3 protein.

Role of Complement System in Disease

Innate immune mechanisms including the complement system are the first line of a higher organism’s defense against infective agents coming from the external environment. Impairment of these basic mechanisms can cause a diverse spectrum of diseases. The reasons for the complement system malfunctioning may be different. They are often the result of mutations in genes encoding the complement cascade proteins or regulatory proteins.

Deficiencies of the C3 and other complement components, contribute to the emergence of recurrent bacterial, viral and fungal infections. MBL also plays a major protective role in the early stages of infection and in the control of inflammation. Its deficit is one of the most common reasons for human immunodeficiency, observed in microbial infections as well as in autoimmune diseases such as rheumatoid arthritis. On the other hand, the excessive activation of complement proteins is often discovered to be the reason for many diseases. These include e.g. autoimmune diseases, Alzheimer's syndrome, schizophrenia, atypical hemolytic-uremic syndrome, angioedema, macular degeneration, and Crohn's disease.

Complement is responsible for immune inflammatory response in adipose tissues which has been implicated in the development of obesity and can lead to tissue inflammation and eventually insulin resistance. Lack of regulation of the classical complement pathway through the deficiency in C1-inhibitor results in episodic angioedema. C1-inhibitor defiency can be hereditary or acquired, resulting in hereditary or acquired angioedema. Addtionally, deficiency in the C1q protein of the classical complement pathway can lead to development of systemic lupus erythematosus.

Immunotherapies have been developed to detect and destroy cells infected by the HIV virus via classical complement activation utilizing synthetic peptides that target conserved regions in HIV specific proteins and induce an antibody specific immune response through IgG antibodies.

In COVID-19, the SARS-CoV-2 nucleocapsid protein triggers activation of the lectin pathway of the complement system through interaction with mannose binding lectin (MBL)-associated serine protease (MASP)2. Released soluble N protein dimers interact with MASP-2, further accelerating MASP-2 activation and activation of the complement system. The positive feedback through cell lysis and release of N-protein leads to elevation of pro-inflammatory cytokines, characterized as cytokine storm.


References:

  1. Reis, Mastellos, Hajishengallis, Lambris: "New insights into the immune functions of complement." in: Nature reviews. Immunology, Vol. 19, Issue 8, pp. 503-516, (2020) (PubMed).
  2. Vandendriessche, Cambier, Proost, Marques: "Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis." in: Frontiers in cell and developmental biology, Vol. 9, pp. 624025, (2021) (PubMed).
  • (3) Xaria X Li, et al. : "The Complement Receptor C5aR2: A" Powerful Modulator of Innate and Adaptive Immunity" in: J Immunol, (2019
  • (4) Gao T, et al. : "Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation." in: medRxiv, (2020)
  • (4) Risitano AM, et al. : “Complement as a target in COVID-19?” in: Nature Reviews Immunology 65(12): 1337-45, (2020)

Complement System Related Proteins

Product
Source
Cat. No.
Validations
Quantity
Delivery
Source HEK-293 Cells
Cat. No. ABIN7274333
Validations
  • (4)
Quantity 100 μg
Delivery 11 to 13 Days
Source HEK-293 Cells
Cat. No. ABIN7274038
Validations
  • (3)
Quantity 100 μg
Delivery 11 to 13 Days
Source HEK-293 Cells
Cat. No. ABIN7274036
Validations
  • (2)
Quantity 100 μg
Delivery 11 to 13 Days
Source HEK-293 Cells
Cat. No. ABIN7491549
Validations
  • (2)
Quantity 100 μg
Delivery 25 to 31 Days
Source HEK-293 Cells
Cat. No. ABIN7092743
Validations
  • (1)
Quantity 100 μg
Delivery 12 to 14 Days
Source HEK-293 Cells
Cat. No. ABIN7198986
Validations
Quantity 100 μg
Delivery 11 to 14 Days
Source HEK-293 Cells
Cat. No. ABIN7534086
Validations
Quantity 100 μg
Delivery 13 to 14 Days
Source HEK-293 Cells
Cat. No. ABIN7505776
Validations
Quantity 100 μg
Delivery 11 to 14 Days
Source HEK-293 Cells
Cat. No. ABIN2715516
Validations
  • (1)
Quantity 20 μg
Delivery 11 Days
Source HEK-293 Cells
Cat. No. ABIN2712454
Validations
  • (1)
Quantity 20 μg
Delivery 11 Days

Complement System Related Antibodies

Product
Reactivity
Clonality
Application
Cat. No.
Quantity
Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, IHC (p)
Cat. No. ABIN657704
Quantity 400 μL
Datasheet Datasheet
Reactivity Mouse
Clonality Polyclonal
Application WB, IHC, IP, ICC
Cat. No. ABIN7433423
Quantity 100 μL
Datasheet Datasheet
Reactivity Rat
Clonality Polyclonal
Application WB, IHC, IP, ICC
Cat. No. ABIN7443419
Quantity 100 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, IHC, IP, ICC
Cat. No. ABIN7435277
Quantity 100 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, IHC, IP, ICC
Cat. No. ABIN7432772
Quantity 100 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, IHC (p)
Cat. No. ABIN656025
Quantity 400 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, IHC, IP, IF
Cat. No. ABIN3015550
Quantity 100 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, FACS, ELISA, IHC, IF
Cat. No. ABIN5539670
Quantity 100 μg
Datasheet Datasheet
Reactivity Mouse, Rat
Clonality Polyclonal
Application WB, IHC (p)
Cat. No. ABIN3044294
Quantity 100 μg
Datasheet Datasheet
Reactivity Human
Clonality Monoclonal
Application WB, ELISA, IP
Cat. No. ABIN513876
Quantity 100 μg
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, ELISA, IHC, IF
Cat. No. ABIN7148353
Quantity 100 μg
Datasheet Datasheet
Reactivity Human, Mouse
Clonality Polyclonal
Application WB, IHC (fro), ELISA
Cat. No. ABIN1385282
Quantity 100 μL
Datasheet Datasheet
Reactivity Human
Clonality Polyclonal
Application WB, ELISA, ID
Cat. No. ABIN285137
Quantity 1 mL
Datasheet Datasheet
Reactivity Human
Clonality Monoclonal
Application ELISA, WB, IHC (fro)
Cat. No. ABIN284013
Quantity 50 μg
Datasheet Datasheet

Complement System Related ELISA Kits

Product
Sample Type
Analytical Method
Cat. No.
Validations
Quantity
Datasheet
Sample Type Plasma, Serum
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6720575
Validations
  • (1)
  • (6)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6955003
Validations
  • (6)
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Cell Culture Supernatant, Cell Lysate, Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6955030
Validations
  • (2)
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Cell Culture Supernatant, Cell Lysate, Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6955023
Validations
  • (1)
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6955010
Validations
  • (4)
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Cerebrospinal Fluid, Saliva, Serum, Urine
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6975137
Validations
  • (1)
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6966049
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6966022
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6966021
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6966018
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6965287
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Plasma, Serum
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6954998
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Cell Lysate, Tissue Homogenate
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN6955019
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet
Sample Type Cell Culture Supernatant, Milk, Plasma, Saliva, Serum
Analytical Method Quantitative Sandwich ELISA
Cat. No. ABIN1440231
Validations
  • (1)
Quantity 96 tests
Datasheet Datasheet

Classical Pathway

C1QA (Complement Component 1, Q Subcomponent, A Chain):

C1QB (Complement Component 1, Q Subcomponent, B Chain):

C1QC (Complement Component 1, Q Subcomponent, C Chain):

C1R (Complement Component 1, R Subcomponent):

C1S (Complement Component 1, S Subcomponent):

Lectin Pathway

MASP2 (Mannan-Binding Lectin serine Peptidase 2):

MASP1 (Mannan-Binding Lectin Serine Peptidase 1):

MBL2 (Mannose-Binding Lectin (Protein C) 2, Soluble):

FCN1 (Ficolin (Collagen/fibrinogen Domain Containing) 1):

FCN3 (Ficolin (Collagen/fibrinogen Domain Containing) 3 (Hakata Antigen)):

Alternative Pathway

Terminal Pathway

C8A (Complement Component 8, alpha Polypeptide):

C8B (Complement Component 8, beta Polypeptide):

C8G (Complement Component 8, gamma Polypeptide):

Regulators

Extrinsic Pathway

KLKB1 (Kallikrein B, Plasma (Fletcher Factor) 1):

PRSS57 (Protease, Serine, 57):

Complement Receptors

You are here:
Support